PROSPECTS OF TETRAPEPTIDE APPLICATION IN TREATMENT OF CHRONIC BRONCHITIS: MOLECULAR MECHANISMS
Introduction. Chronic bronchitis is one of the socially significant diseases. Accordingly, a search of the new more effective and safe
bronchoprotective drugs is the one of aims of molecular medicine.
The aim of the study. The goal of our research was the investigation of bronchoprotective effects and molecular mechanisms of biological
activity of the AEDL tetrapeptide
Methods. There were used cell cultures method, immunocytochemistry and PCR analysis.
Results. AEDL tetrapeptide regulates Ki67, Mcl-1, p53, CD79, NOS-3 proteins synthesis in the bronchial epithelium cell cultures. It
contributes to the activation of the cell renewal processes as well as to the increase in the functional activity of bronchial epithelial cells. TheAEDL tetrapeptide activates the expression of genes involved in bronchial epithelium differentiation, namely Nkx2.1, SCGB1A1, SCGB3A2,
FoxA1 and FoxA2, as well as of the genes MUC4, MUC5АС, SftpA1, whose reduced expression is known to be related with the development
of chronic bronchitis. The AEDL peptide has been proved to be effective and safe in the oral use in complex treatment of patients with chronic
bronchitis in remission. The pulmonary function indices in these patients normalized after the AEDL tetrapeptide administration.
Conclusion. Thus, the AEDL tetrapeptide epigenetically regulates the gene expression and synthesis of proteins, participating in
differentiation and functional activity of bronchial epithelium. This lies at the base of the bronchoprotective effect of this tetrapeptide.
Keywords:
AEDL tetrapeptide, bronchial epithelium, signaling molecules, gene expression, chronic bronchitis